Vimarsana
Biggest News Aggregation in the World

Page 2 - China Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from China Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In China Guide Today - Breaking & Trending Today

华泰证券:脱发诊疗千亿级市场正起航 从刚需向美学发展 _ 东方财富网 - Vimarsana News

华泰证券:脱发诊疗千亿级市场正起航 从刚需向美学发展 _ 东方财富网

   脱发行业:高人群基数+低渗透+强推广,催生千亿市场。卫健委数据显示2020年我国超2.5亿脱发人群(雄激素性脱发占比90%以上),2020年中国脱发药物治疗市场规模~7亿元,毛发医疗服务市场规模~185亿元,我们预计未来十年脱发行业有望迎来快速发展(2021-2031E CAGR=22%),基于:   1) 人群特征的改变:脱发群体年轻化(26-30岁年龄段占比脱发人群42%,艾媒咨询2020),年轻人重视外表且消费意愿更强,同时女性防脱市场亦快速崛起(依从性更优);   2) 产å...

高瓴、安进等巨头加持!首家"A+H+N"三地上市药企来了|新药 - Vimarsana News

高瓴、安进等巨头加持!首家"A+H+N"三地上市药企来了|新药

2021-06-29 01:12:04 来源: 中国证券报 举报 分享至 分享至好友和朋友圈   6月28日,上交所发布科创板上市委2021年第43次审议会议结果公告,百济神州首发获通过。中金公司及高盛高华为联合保荐人。   公司此次科创æ...

Source: 163.com
高瓴、安进等巨头加持!首家"A+H+N"三地上市药企来了-私募-金融界 - Vimarsana News

高瓴、安进等巨头加持!首家"A+H+N"三地上市药企来了-私募-金融界

  目前,公司商业化产品及临床阶段候选药物共有47款,包括8款商业化阶段药物、4款已申报候选药物和35款临床阶段候选药物。3款由百济神州自主研发的创新药物BTK小分子抑制剂百悦泽、抗PD-1单抗百泽安和PARP抑制剂百汇泽处于商业化阶段。   其中,百悦泽于2019年11月获得美国食品和药品监督管理局(FDA)加速批准上市,成为我国首个在美获批上市的中国本土自主研发抗癌新药,改写了中国抗癌新药“只进不出”的历史,实现国产新药出海“零ç...

Source: jrj.com.cn
How China has been transforming international education to become a leading host of students - Vimarsana News

How China has been transforming international education to become a leading host of students

Once seen as mainly as a source of international students, China has for a decade been strategically repositioning itself as a provider of international education.

How China has been transforming international education to become a leading host of students - Vimarsana News

How China has been transforming international education to become a leading host of students

When Australians think of international education and China, they typically consider the country as a source of international students — Australia’s largest. But China is now one of the leading host countries of international students in the world. China’s level of international education policymaking over the past decade, backed up by strategic priorities, has been unprecedented. My recently published research shows Chinese universities are learning to reconcile the different forces of local, national and global demands. They aim to: calibrate to the Chinese government’s grand schem...